Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The deadline to apply for the INVEST Pitch Perfect Contest is January 24! In addition to a business profile, Pitch Perfect winners also receive a $20,000 branding advertising package from MedCity News.
This first of a two-part article examines key challenges healthcare technology companies must address to survive the “Death Valley” curve and increase their chances for success when moving from technology development to market acceptance.
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions.
In response to emailed questions, the founders of MucoLife Therapeutics shared their company's approach, which is designed to help people with COPD, cystic fibrosis, asthma, and pulmonary fibrosis.
Inspired by the speed and ease of at-home Covid-19 tests, OncoSwab is developing a test for lung cancer that detects signs of the disease from a nasal swab. The test could become an alternative to the medical imaging currently used to screen for lung cancer.
Valora Therapeutics’ antibody lectin chimeras, or AbLecs, target glyco-immune checkpoints, pathways that modulate cellular communication with the immune system. The startup’s science is based on research from Carolyn Bertozzi, a Stanford professor who was awarded the 2022 Nobel Prize in Chemistry.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Among the topics INVEST will highlight are AI in life sciences, the investor perspective in healthcare and strategic priorities for hospitals.
Building trust while simultaneously building products, selling, recruiting, and fundraising can feel impossible. But it's required whether you have the time or not, and it doesn’t stop no matter how big you grow.
While startups in highly regulated industries like healthcare and finance are almost certain to face heightened scrutiny, there are controllable factors that can offset these challenges.
Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington professor of biochemistry recently awarded the Nobel Prize in Chemistry for his work in computational protein design.
Novo Holdings led the Series A investment in Kivu Bioscience, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary.